164 related articles for article (PubMed ID: 26687594)
1. 57th American Society of Hematology Annual Meeting.
Smith LL
Lancet Oncol; 2016 Feb; 17(2):142. PubMed ID: 26687594
[No Abstract] [Full Text] [Related]
2. 58th American Society of Hematology Annual Meeting.
Smith LL
Lancet Haematol; 2017 Jan; 4(1):e13-e14. PubMed ID: 28041582
[No Abstract] [Full Text] [Related]
3. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Tallman M
Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
[No Abstract] [Full Text] [Related]
4. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
5. The 51st annual meeting of the American Society of Hematology.
Cunningham S; Muneer S; Ranganathan A; Shrader M
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):11-20. PubMed ID: 20223725
[No Abstract] [Full Text] [Related]
6. Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of Hematology.
Stone RM
Expert Rev Hematol; 2013 Apr; 6(2):127-9. PubMed ID: 23547861
[TBL] [Abstract][Full Text] [Related]
7. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma.
Glavey SV; Ghobrial IM
Expert Rev Hematol; 2015 Jun; 8(3):273-5. PubMed ID: 25804827
[TBL] [Abstract][Full Text] [Related]
8. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
9. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962).
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27466629
[No Abstract] [Full Text] [Related]
10. Geriatric Hematology Research presented at the 2018 American Society of Hematology Annual Meeting: Young International Society of Geriatric Oncology Perspective Paper.
Loh KP; Christofyllakis K; Huang LW; Mims A
J Geriatr Oncol; 2019 Mar; 10(2):186-191. PubMed ID: 30661875
[No Abstract] [Full Text] [Related]
11. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J
Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356
[No Abstract] [Full Text] [Related]
12. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
13. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA; December 8-11, 2007.
Clin Lymphoma Myeloma; 2008 Apr; 8(2):77-86. PubMed ID: 18564453
[No Abstract] [Full Text] [Related]
14. Midostaurin Gets FDA Nod for AML.
Cancer Discov; 2017 Jul; 7(7):OF5. PubMed ID: 28526740
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin + Chemo Ups AML Survival.
Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
[TBL] [Abstract][Full Text] [Related]
16. Midostaurin for the treatment of acute myeloid leukemia.
Patnaik MM
Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase inhibition as an anticancer strategy.
Hilton JF; Shapiro GI
J Clin Oncol; 2014 Jan; 32(1):57-9. PubMed ID: 24043748
[No Abstract] [Full Text] [Related]
18. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
19. Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias.
Lipka DB; Wagner MC; Dziadosz M; Fischer T
Leukemia; 2016 Oct; 30(10):2090-2093. PubMed ID: 27137475
[No Abstract] [Full Text] [Related]
20. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
